Celgene Reports Fourth Quarter and Full Year 2015 Operating and Financial Results

Go back to Celgene Reports Fourth Quarter and Full Year 2015 Operating and Financial Results

Jefferies Cuts Price Target on Celgene (CELG) as FX Weighs on Near-Term

January 29, 2016 9:07 AM EST

Jefferies maintained a Buy rating on Celgene (NASDAQ: CELG), and cut the price target to $146.00 (from $149.00), following the company's 4Q earnings report. FX volatility appears to be weighing a bit on near-term performance prospects. CELG noted that the ~$700-800M negative top-line impact... More

Celgene (CELG) Misses Q4 EPS by 4c

January 28, 2016 7:32 AM EST

Celgene (NASDAQ: CELG) reported Q4 EPS of $1.18, $0.04 worse than the analyst estimate of $1.22. Revenue for the quarter came in at $2.54 billion versus the consensus estimate of $2.54 billion.

GUIDANCE:

Celgene sees Q1 2016 EPS of $1.27-$1.30, versus the consensus of... More